A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: November 12, 2009
Last updated: February 16, 2012
Last verified: June 2011
To determine if an on demand dosing of 50 mg or 150 mg of GSK557296 demonstrates superior efficacy with respect to duration of intra vaginal ejaculatory latency time (IELT) during an 8 week study period compared to placebo in men with primary premature ejaculation. An assessment of the safety and tolerability of all doses of GSK557296 will be performed as well as an assessment for change in the Index of Premature Ejaculation (IPE) from baseline and at the end of the 8 weeks of treatment. During the active treatment period study participants will be limited to a maximum of 40 doses of GSK557296, or placebo, spilt as 20 doses for both 4 week intervals.

Condition Intervention Phase
Premature Ejaculation
Drug: GSK557296
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men With Premature Ejaculation

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • IELT: Time from vaginal penetration (start stopwatch) until ejaculation (stop stopwatch), assessed after every attempt at intercourse with 50mg, 150mg GSK557296 or placebo therapy, compared over all 8 weeks of treatment or until premature discontinuation [ Time Frame: 8 weeks of active treatment ]

Secondary Outcome Measures:
  • IELT compared after each 4-week treatment period, or until premature discontinuation [ Time Frame: 4 week ]
  • IELT compared after the first dose of 50mg or 150mg GSK557296 or placebo [ Time Frame: 4 weeks ]
  • IELT change baseline compared after each 4-week treatment period and over all 8 weeks of 50mg or 150mg GSK557296 or placebo therapy, or until premature discontinuation [ Time Frame: 4-week, 8-week ]
  • IELT change from baseline compared after the first dose of 50mg or150mg GSK557296 or placebo [ Time Frame: 4 weeks ]
  • plasma pharmacokinetics (e.g. AUC, Tmax, Cmax) of GSK557296 will be obtained (as data permits). [ Time Frame: by week 4 ]
  • dose/exposure response relationship using PK/PD modeling for selected endpoints, as data permit. [ Time Frame: by week 4 ]
  • Tabulation of shifts in vital signs including ECGs as assessed by change from visits 1 and 2 compared to visits 3 and 4 for placebo and pooled GSK557296 treated groups and individual GSK557296 50mg and 150mg groups [ Time Frame: screening, week 4, week 8 and week 12 ]
  • Tabulations of shifts in serum laboratory data collected at visit 1 compared to visit 3 and 4 for placebo and pooled GSK557296 treated groups and individual GSK557296 50mg and 150mg group [ Time Frame: screening , week 8 ]
  • Tabulation of adverse events group by body system and preferred term, for placebo and pooled GSK557296 treated group and individual GSK557296 50mg and 150mg [ Time Frame: 12 weeks ]

Enrollment: 75
Study Start Date: December 2009
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
Drug: placebo
Active Comparator: 50 mg
50 mg GSK557296
Drug: GSK557296
50 mg GSK557296
Other Name: 50 mg
Active Comparator: 150 mg
150 mg GSK557296
Drug: GSK557296
150 mg GSK557296
Other Name: 150 mg


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males with primary PE, according to the ISSM Consensus Definition. Defined as, a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and, inability to delay ejaculation on all or nearly all vaginal penetrations; and, negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy
  2. Stable heterosexual relationship, with a single non pregnant, nonlactating female partner using adequate contraception (as confirmed by oral questioning of male study subject) in a relationship of greater than >4 months duration. This same partner will be the one with whom the subject makes and records all IELT attempts during the duration of the study.
  3. Aged between 18 and 50 years (i.e. subjects must not have completed their 50th year birthday at the time of screening, but can turn 50 years during the course of the study).
  4. The subject must make at least four attempts at sexual intercourse on four separate days during the untreated run in period.
  5. The average intravaginal ejaculatory latency time must be <65 seconds based on the study-provided stop watch assessments

Exclusion Criteria:

  1. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result and positive HIV antibody and or confirmatory ELISA test at screening.
  2. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

Previous or Current Medical Conditions

  1. Erectile dysfunction (defined as IIEF-EF domain score < 22)
  2. Active or recent (< 6 months) history of prostatitis, as determined by patient symptoms or treatment seeking for newly diagnosed or flare of symptoms related to previously diagnosed prostatitis.
  3. Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
  4. Presence of penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) that in the opinion of the investigator would significantly impair sexual performance.
  5. Prior implantation of penile implant for erectile dysfunction
  6. Primary hypoactive sexual desire.
  7. Spinal cord injury.
  8. History of seizures, within last 6 months.
  9. History of prostate cancer treated or untreated.
  10. History of prostatectomy or prostate procedures for any cause.
  11. Clinically significant chronic hematological disease which may lead to priapism such as sickle cell anemia, multiple myeloma or leukemia.
  12. Significant active peptic ulceration.
  13. Presence of the following conditions prior to screening: myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically evident congestive heart failure, cardiac pacemaker, or cerebrovascular accident.
  14. Cardiac arrhythmia: significant cardiac arrhythmia shown on screening ECG, or a known or suspected history of significant cardiac arrhythmias within six months prior to screening. i.e., pre-existing syndromes, sinus pause > 3 seconds, non-sustained ventricular tachycardia (3 consecutive ectopic beats), sustained ventricular tachycardia (30 consecutive ectopic beats), sustained supraventricular tachycardia (30 consecutive ectopic beats), accessory pathway tachycardia, bradycardia (heart rate < 50 beats per minute), atrial flutter, atrial fibrillation, ectopic pacemaker, sick sinus syndrome, ventricular block (second or third degree), or bundle branch block. Uncontrolled atrial fibrillation/flutter (ventricular response rate less than or equal to 100 bpm) at the screening visit (Visit 1).
  15. History of congenital QT prolongation and/or QTc interval >450msec at screening visit (Visit 1) using the Bazett formula.
  16. Mean systolic cuff BP > 140 mmHg, as assessed by three measurements taken in sequence within 5-10ming of last measure. Taken with the study subject in a supine position at the screening visit (Visit 1).
  17. Mean diastolic cuff BP >90 mmHg, as assess by three measurements taken in sequence within 5-10 minutes of the last measure. Taken with the study subject in a supine position at the screening visit (Visit 1).
  18. History of malignancy within the past five years (other than squamous or basal cell skin cancer).
  19. Any condition which would preclude sexual activity.

Concomitant Medications

  1. No concomitant medications maybe used within 7 days of Visit 1 and or at any time during the study including oral medications, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter herbal or non-prescription medications, and products purchased via the internet or mail order pharmacies. During the course of the study concomitant medication use can be considered upon consultation and prior agreement with primary investigator and medical monitor. Specific exceptions for asthmatic patients and patients with allergic rhinitis, who are on stable doses of inhaled or intra nasal agents as prescribed by their health care providers, and who have had no adjustments in their prescribed and or actual use within the last 60 days. Agents which are known or expected to have significant systemic exposures as a result of inhaled or intra-nasal use or to have known CYP3A4 drug-drug interaction potential are not included in this exemption.
  2. Subjects who have received any investigational drug (including placebo) within 30 days of the screening visit or 5 half lives of the investigational drug whichever is longer (Visit 1).

Abnormal Laboratory Values

  1. Subjects who have a serum total testosterone level >25% below the lower limit of normal according to the range of the testing laboratory, when obtained in the morning versus in the afternoon, from screening lab which will need to be evaluated prior to randomization.
  2. Subjects with a clinically significant elevation of serum creatinine of > 2.0 when obtained from a screening lab which will need to be evaluated prior to randomization.
  3. Subject with a clinically significant elevation of AST of > 126 and/or ALT of > 144 when obtained from a screening lab which will need to be evaluated prior to randomization.
  4. Screening PSA > 4.0 ng/ml
  5. TSH outside the normal reference ranges at visit 1
  6. Free Triiodothyronine [T3] outside the normal reference ranges at visit 1
  7. Free Thyroxine T4 outside the normal reference ranges at visit 1

Other exclusion criteria

  1. Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
  2. Subjects with known hypersensitivity to GSK557296 or any component of the investigational medication.
  3. Subjects who are illiterate or unable to understand the questionnaires or the subject diary.
  4. Subjects who are unwilling or unable to complete the subject diary.
  5. Subjects who are unwilling to be randomized to placebo.
  6. Subject whose sexual partner is actively trying to conceive, and or is unwilling to use a reliable form of birth control as outlined in Section 8.1 for the duration of the trial. Or whose female partner is breast feeding.
  7. Subjects, who in the opinion of the investigator, would be non-compliant with the majority of the visits scheduled or study procedures.
  8. History of sensitivity to heparin or heparin-induced thrombocytopenia (for subjects at sites where PK studies are planned).
  9. Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 1 month prior to screening.
  10. Consumption of seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication, and for the duration of the study.
  11. Subjects who have consumed alcohol within 24 hours will have their PK session rescheduled.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01021553

United States, California
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
San Jose, California, United States, 95128
United States, Indiana
GSK Investigational Site
Fort Wayne, Indiana, United States, 46825
United States, New York
GSK Investigational Site
New York, New York, United States, 10016
United States, Pennsylvania
GSK Investigational Site
Bala Cynwyd, Pennsylvania, United States, 19004
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01021553     History of Changes
Other Study ID Numbers: 109059 
Study First Received: November 12, 2009
Last Updated: February 16, 2012

Keywords provided by GlaxoSmithKline:
Proof of Concept
Double Blind

Additional relevant MeSH terms:
Premature Birth
Premature Ejaculation
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on January 23, 2017